JARDIANCE (EMPAGLIFLOZIN)
JARDIANCE (EMPAGLIFLOZIN) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: JARDIANCE; Generic name: EMPAGLIFLOZIN; Drug class: Sodium-Glucose Cotransporter 2 Inhibitor [EPC].
| Brand name | JARDIANCE |
|---|---|
| Generic name | EMPAGLIFLOZIN |
| Drug class | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] |
| Manufacturer | A-S Medication Solutions |
| Used for | 1 INDICATIONS AND USAGE JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. ( 1 ) To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease |
| Dosage | 2 DOSAGE AND ADMINISTRATION Assess volume status and correct volume depletion before initiating ( 2.1 ) Recommended dose is 10 mg once daily in the morning, taken with or without food ( 2.2 ) For additional glycemic control, dose may be increased to 25 mg in patients tolerating JARDIANCE ( 2.2 ) 2.1 Prior to Initiation of JARDIANCE Assess renal function before initiating JARDIANCE and as clinically indicated [see Warnings and Precautions (5.2) ] . In patients with volume depletion, correct this |
| Active ingredient(s) | EMPAGLIFLOZIN |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1782b947-4a72-4feb-a488-1469d9af82bd |